Published in Curr Psychiatry Rev on May 01, 2014
From big data analysis to personalized medicine for all: challenges and opportunities. BMC Med Genomics (2015) 1.04
Empirical evaluation of the Q-Genie tool: a protocol for assessment of effectiveness. BMJ Open (2016) 0.75
Initial sequencing and analysis of the human genome. Nature (2001) 212.86
MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 198.59
The sequence of the human genome. Science (2001) 101.55
Molecular portraits of human breast tumours. Nature (2000) 94.14
The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology (1982) 79.76
A method and server for predicting damaging missense mutations. Nat Methods (2010) 78.53
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
Finding the missing heritability of complex diseases. Nature (2009) 67.95
An integrated map of genetic variation from 1,092 human genomes. Nature (2012) 59.82
A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15
Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med (2008) 57.29
Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A (2009) 54.68
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med (2009) 46.35
Finishing the euchromatic sequence of the human genome. Nature (2004) 41.40
MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet (2004) 37.83
Common SNPs explain a large proportion of the heritability for human height. Nat Genet (2010) 35.02
Targeted capture and massively parallel sequencing of 12 human exomes. Nature (2009) 33.96
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (2005) 32.41
Integrating common and rare genetic variation in diverse human populations. Nature (2010) 32.30
Exome sequencing identifies the cause of a mendelian disorder. Nat Genet (2009) 32.06
The epigenomics of cancer. Cell (2007) 30.91
Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic Acids Res (2005) 30.44
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet (2005) 29.45
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A (2004) 28.29
ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med (2013) 22.73
Common genetic variation and human traits. N Engl J Med (2009) 21.03
Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation (2007) 20.44
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Epigenetics in cancer. N Engl J Med (2008) 17.36
Rare variants of IFIH1, a gene implicated in antiviral responses, protect against type 1 diabetes. Science (2009) 16.35
Evaluating the yield of medical tests. JAMA (1982) 14.05
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol (2002) 13.81
Patterns and rates of exonic de novo mutations in autism spectrum disorders. Nature (2012) 13.71
De novo mutations revealed by whole-exome sequencing are strongly associated with autism. Nature (2012) 13.61
Discovering genotypes underlying human phenotypes: past successes for mendelian disease, future approaches for complex disease. Nat Genet (2003) 13.60
Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A (2003) 13.00
Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med (2009) 12.63
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med (2000) 12.34
Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell (2012) 12.32
Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol (2004) 12.03
SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med (2008) 11.31
Phenotypic plasticity and the epigenetics of human disease. Nature (2007) 10.37
Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med (2008) 9.83
Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med (2008) 9.68
Gene-expression signatures in breast cancer. N Engl J Med (2009) 9.23
Making a definitive diagnosis: successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease. Genet Med (2011) 9.03
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med (2005) 8.77
Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med (2008) 8.70
Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med (2004) 8.62
Social networkers' attitudes toward direct-to-consumer personal genome testing. Am J Bioeth (2009) 8.28
Structural variation in the human genome and its role in disease. Annu Rev Med (2010) 7.85
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med (2006) 7.31
The incidentalome: a threat to genomic medicine. JAMA (2006) 7.24
Computational methods for discovering structural variation with next-generation sequencing. Nat Methods (2009) 7.20
A randomized trial of genotype-guided dosing of warfarin. N Engl J Med (2013) 7.18
A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med (2013) 7.09
Rare and common variants: twenty arguments. Nat Rev Genet (2012) 6.67
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst (2000) 6.38
Cardiovascular disease risk prediction with and without knowledge of genetic variation at chromosome 9p21.3. Ann Intern Med (2009) 6.00
Performance of common genetic variants in breast-cancer risk models. N Engl J Med (2010) 5.79
Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J Am Coll Cardiol (2010) 5.07
What is population health? Am J Public Health (2003) 5.06
American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol (2010) 4.93
The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood (2005) 4.91
Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med (2006) 4.88
Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol (2010) 4.81
Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst (2010) 4.80
Genomic medicine--a primer. N Engl J Med (2002) 4.77
The predictive capacity of personal genome sequencing. Sci Transl Med (2012) 4.64
Assessing the combined impact of 18 common genetic variants of modest effect sizes on type 2 diabetes risk. Diabetes (2008) 4.57
Comparison of next-generation sequencing systems. J Biomed Biotechnol (2012) 4.56
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther (2008) 4.54
Predictive testing for complex diseases using multiple genes: fact or fiction? Genet Med (2006) 4.48
Bayesian inference analyses of the polygenic architecture of rheumatoid arthritis. Nat Genet (2012) 4.41
An agenda for personalized medicine. Nature (2009) 4.14
Exome sequencing and the genetic basis of complex traits. Nat Genet (2012) 4.11
Predictive, personalized, preventive, participatory (P4) cancer medicine. Nat Rev Clin Oncol (2011) 4.02
Population screening in the age of genomic medicine. N Engl J Med (2003) 3.89
Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene (2003) 3.83
First FDA authorization for next-generation sequencer. N Engl J Med (2013) 3.70
ATP-sensitive potassium channelopathies: focus on insulin secretion. J Clin Invest (2005) 3.56
Genomic medicine--an updated primer. N Engl J Med (2010) 3.48
Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine. J Proteome Res (2004) 3.46
Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human. Nature (2012) 3.41
A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation (2012) 3.30
A critical appraisal of the scientific basis of commercial genomic profiles used to assess health risks and personalize health interventions. Am J Hum Genet (2008) 3.25
Keeping pace with the times--the Genetic Information Nondiscrimination Act of 2008. N Engl J Med (2008) 3.22
A readers' guide to the interpretation of diagnostic test properties: clinical example of sepsis. Intensive Care Med (2003) 3.06
From disease association to risk assessment: an optimistic view from genome-wide association studies on type 1 diabetes. PLoS Genet (2009) 2.99
Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry (2004) 2.98
The $1,000 genome, the $100,000 analysis? Genome Med (2010) 2.79
Improving validation practices in "omics" research. Science (2011) 2.73
Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J Cyst Fibros (2008) 2.56
The ethical hazards and programmatic challenges of genomic newborn screening. JAMA (2012) 2.54
Has the revolution arrived? Nature (2010) 2.47
Structural basis of caspase inhibition by XIAP: differential roles of the linker versus the BIR domain. Cell (2001) 2.43
Human genome 10th anniversary. Waiting for the revolution. Science (2011) 2.38
Jumping on the Train of Personalized Medicine: A Primer for Non-Geneticist Clinicians: Part 2. Fundamental Concepts in Genetic Epidemiology. Curr Psychiatry Rev (2014) 0.77
Jumping on the Train of Personalized Medicine: A Primer for Non-Geneticist Clinicians: Part 1. Fundamental Concepts in Molecular Genetics. Curr Psychiatry Rev (2014) 0.76
Genetic association of rs1344706 in ZNF804A with bipolar disorder and schizophrenia susceptibility in Chinese populations. Sci Rep (2017) 0.75